| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | -163.12M | 12.44M | 184.74M | 103.85M | 37.06M |
| Gross Profit | -180.65M | -47.69M | 65.44M | 59.84M | 26.62M |
| EBITDA | -47.21M | 25.21M | 168.03M | 89.97M | 15.76M |
| Net Income | -36.50M | 12.71M | 31.48M | 34.61M | 8.86M |
Balance Sheet | |||||
| Total Assets | 445.56M | 591.80M | 548.90M | 407.06M | 199.61M |
| Cash, Cash Equivalents and Short-Term Investments | 8.82M | 533.33M | 495.87M | 346.94M | 49.74M |
| Total Debt | 37.18M | 61.92M | 68.98M | 211.59M | 113.29M |
| Total Liabilities | 331.19M | 402.86M | 365.44M | 258.13M | 110.72M |
| Stockholders Equity | 54.70M | 188.94M | 183.47M | 148.93M | 88.87M |
Cash Flow | |||||
| Free Cash Flow | -80.46M | 19.16M | 84.50M | -55.26M | -56.56M |
| Operating Cash Flow | -43.51M | 19.20M | 84.59M | -55.22M | -56.54M |
| Investing Cash Flow | -103.63K | -31.00K | -198.00K | -335.00K | -70.00K |
| Financing Cash Flow | 18.17M | -55.58M | -32.61M | 51.86M | 74.14M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | £41.26M | 3.46 | 8.28% | ― | 11.71% | 31.15% | |
73 Outperform | £92.71M | 2.79 | 11.93% | ― | 17.35% | 91.55% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
61 Neutral | £192.50M | 2.44 | -965.56% | 4.74% | ― | ― | |
60 Neutral | ― | -11.52 | 0.93% | 8.48% | ― | ― | |
55 Neutral | £382.45M | 8.64 | 21.54% | ― | 7.90% | ― | |
44 Neutral | £8.39M | -1.65 | -58.13% | ― | -44.60% | -658.40% |
Litigation Capital Management has disclosed that an Australian court has ruled against the claimant in a commercial case that the firm funded, reversing expectations after it had flagged an imminent judgment on this small investment earlier in March. The company committed A$1.4 million of shareholder capital to the matter and had after-the-event insurance in place to mitigate adverse costs, and it is now reviewing the judgment with the funded party and legal advisers to determine its next steps.
While the financial exposure on this single case is limited relative to LCM’s broader portfolio, the loss underscores the inherent uncertainty and binary risk profile of litigation funding investments. Stakeholders will be watching how LCM’s response and any potential appeal or strategic adjustment may influence its risk management approach, portfolio performance, and perception within the specialist dispute finance sector.
The most recent analyst rating on (GB:LIT) stock is a Sell with a £7.50 price target. To see the full list of analyst forecasts on Litigation Capital Management stock, see the GB:LIT Stock Forecast page.
Litigation Capital Management has reported a significant legal victory for a trademark case it funded on behalf of Sydney designer Katie Perry against singer Katy Perry and related entities, after the High Court of Australia upheld the designer’s appeal. The case, backed with A$3.3 million of LCM’s balance sheet capital, will now return to the Full Court to resolve outstanding issues including costs and damages, which will determine the company’s ultimate return on the investment.
The firm also expects an imminent judgment on another smaller case with A$1.4 million of shareholder capital at risk, which it will disclose once handed down. LCM said it plans to schedule its half-year results presentation around the end of March to give shareholders a more substantive update on these outcomes and the progress of its ongoing strategic review, underlining the importance of these case resolutions for investors monitoring its performance and capital deployment.
The most recent analyst rating on (GB:LIT) stock is a Hold with a £7.50 price target. To see the full list of analyst forecasts on Litigation Capital Management stock, see the GB:LIT Stock Forecast page.
Litigation Capital Management has secured an extension of its debt covenant waiver from lender Northleaf, pushing the expiry from the end of February 2026 to 15 April 2026. During this extended waiver period, the interest rate on the loan remains elevated by 2.00% per annum, in line with the terms of the original waiver and without any additional one-off fee.
The company said the ongoing waiver underscores Northleaf’s continued support while LCM advances the Strategic Review it launched in September 2025 to resolve its longer-term capital structure. Management intends to update the market on the review’s progress in due course, signalling that decisions on funding and balance sheet strategy remain a key focus for stakeholders.
The most recent analyst rating on (GB:LIT) stock is a Sell with a £10.00 price target. To see the full list of analyst forecasts on Litigation Capital Management stock, see the GB:LIT Stock Forecast page.
Litigation Capital Management Limited reported a significant positive development in the high-profile international arbitration it funded against the Republic of Poland, after a Singapore court fully rejected Poland’s application to set aside a substantial Energy Charter Treaty award. The underlying case, which previously resulted in awards of £252 million plus interest under the ECT and £183 million plus interest under the Australia-Poland Bilateral Investment Treaty (with no double recovery allowed), has seen LCM invest US$11.3 million alongside its Fund I investors and now carries a contractual entitlement of about US$71.9 million in potential proceeds, of which US$18.0 million would accrue to LCM shareholders and US$53.9 million to Fund I investors; however, the company does not expect to earn a performance fee from Fund I on this matter due to earlier adverse fund outcomes, and any final benefit remains subject to a likely appeal by Poland and the timing of its resolution.
The most recent analyst rating on (GB:LIT) stock is a Sell with a £9.00 price target. To see the full list of analyst forecasts on Litigation Capital Management stock, see the GB:LIT Stock Forecast page.
Litigation Capital Management has secured an extension of its debt covenant waiver from lender Northleaf Capital Partners to 31 January 2026, with the interest rate on the loan remaining 2 percentage points higher during the extended waiver period and no additional one-off waiver fee payable. The extension signals continued lender support while LCM progresses its ongoing strategic review, first announced in mid-September, with management planning to update the market on the review’s progress in the new year.
The most recent analyst rating on (GB:LIT) stock is a Hold with a £9.00 price target. To see the full list of analyst forecasts on Litigation Capital Management stock, see the GB:LIT Stock Forecast page.
Litigation Capital Management has disclosed that the Federal Court of Australia has quantified adverse costs totalling A$32.4 million in the unsuccessful Queensland electricity class action it funded against Stanwell Corporation and CS Energy, with A$16.2 million payable to each defendant. After applying its after-the-event insurance, LCM faces an uninsured exposure of A$12.9 million, with the balance to be met by Fund 1 investors; the case is under appeal with a hearing scheduled for March 2026, and the company remains in discussions with its principal lender while its previously announced strategic review continues, underscoring both the financial impact and the ongoing uncertainty for stakeholders around this high-cost litigation.
The most recent analyst rating on (GB:LIT) stock is a Hold with a £9.00 price target. To see the full list of analyst forecasts on Litigation Capital Management stock, see the GB:LIT Stock Forecast page.